Cullinan Associates Inc Abb Vie Inc. Transaction History

Cullinan Associates Inc

  • $1.4 Billion
  • Q1 2025

A detailed history of Cullinan Associates Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Cullinan Associates Inc holds 91,716 shares of ABBV stock, worth $16.8 Million. This represents 1.38% of its overall portfolio holdings.

Number of Shares
91,716
Previous 93,777 2.2%
Holding current value
$16.8 Million
Previous $16.7 Million 15.31%
% of portfolio
1.38%
Previous 1.08%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 22, 2025
SELL
$169.2 - $216.66 $348,721 - $446,536
-2,061 Reduced 2.2%
91,716 $19.2 Million
Q4 2024

Jan 24, 2025
SELL
$164.99 - $203.87 $2.58 Million - $3.19 Million
-15,625 Reduced 14.28%
93,777 $16.7 Million
Q3 2024

Oct 23, 2024
SELL
$163.84 - $199.33 $1.84 Million - $2.23 Million
-11,206 Reduced 9.29%
109,402 $21.6 Million
Q2 2024

Jul 10, 2024
SELL
$154.79 - $180.76 $1.01 Million - $1.18 Million
-6,508 Reduced 5.12%
120,608 $20.7 Million
Q1 2024

Apr 18, 2024
SELL
$159.82 - $182.1 $526,606 - $600,019
-3,295 Reduced 2.53%
127,116 $23.1 Million
Q4 2023

Jan 24, 2024
SELL
$137.6 - $154.97 $2.85 Million - $3.2 Million
-20,680 Reduced 13.69%
130,411 $20.2 Million
Q3 2023

Oct 11, 2023
BUY
$133.59 - $154.65 $1.77 Million - $2.05 Million
13,226 Added 9.59%
151,091 $22.5 Million
Q2 2023

Jul 14, 2023
BUY
$132.51 - $164.9 $697,135 - $867,538
5,261 Added 3.97%
137,865 $18.6 Million
Q1 2023

Apr 05, 2023
BUY
$144.61 - $166.54 $1.02 Million - $1.18 Million
7,080 Added 5.64%
132,604 $21.1 Million
Q4 2022

Jan 11, 2023
BUY
$138.31 - $165.87 $545,909 - $654,688
3,947 Added 3.25%
125,524 $20.3 Million
Q3 2022

Oct 19, 2022
SELL
$134.21 - $153.93 $498,455 - $571,696
-3,714 Reduced 2.96%
121,577 $16.3 Million
Q2 2022

Jul 08, 2022
BUY
$137.62 - $174.96 $1.12 Million - $1.43 Million
8,145 Added 6.95%
125,291 $19.2 Million
Q1 2022

Apr 21, 2022
SELL
$131.98 - $163.75 $1.36 Million - $1.69 Million
-10,297 Reduced 8.08%
117,146 $19 Million
Q4 2021

Jan 07, 2022
BUY
$107.43 - $135.93 $3.96 Million - $5.01 Million
36,841 Added 40.66%
127,443 $17.3 Million
Q3 2021

Oct 08, 2021
BUY
$106.4 - $120.78 $1.31 Million - $1.49 Million
12,353 Added 15.79%
90,602 $9.77 Million
Q2 2021

Jul 07, 2021
BUY
$105.21 - $117.21 $2.5 Million - $2.78 Million
23,757 Added 43.6%
78,249 $8.81 Million
Q1 2021

Apr 20, 2021
BUY
$102.3 - $112.62 $4.16 Million - $4.58 Million
40,661 Added 293.98%
54,492 $5.9 Million
Q4 2020

Jan 14, 2021
BUY
$80.49 - $108.67 $539,283 - $728,089
6,700 Added 93.96%
13,831 $1.48 Million
Q3 2020

Oct 09, 2020
SELL
$85.91 - $100.83 $154,638 - $181,494
-1,800 Reduced 20.15%
7,131 $625,000
Q2 2020

Jul 07, 2020
BUY
$73.37 - $98.18 $149,014 - $199,403
2,031 Added 29.43%
8,931 $877,000
Q1 2020

Apr 01, 2020
SELL
$64.5 - $97.79 $309,600 - $469,392
-4,800 Reduced 41.03%
6,900 $526,000
Q4 2019

Jan 15, 2020
SELL
$72.13 - $90.25 $28,852 - $36,100
-400 Reduced 3.31%
11,700 $1.04 Million
Q3 2019

Oct 01, 2019
BUY
$62.98 - $75.72 $119,662 - $143,868
1,900 Added 18.63%
12,100 $916,000
Q2 2019

Jul 16, 2019
SELL
$65.7 - $83.98 $85,410 - $109,174
-1,300 Reduced 11.3%
10,200 $742,000
Q1 2019

Apr 30, 2019
BUY
$77.14 - $90.79 $256,876 - $302,330
3,330 Added 40.76%
11,500 $927,000
Q3 2018

Oct 19, 2018
SELL
$88.91 - $98.84 $142,256 - $158,144
-1,600 Reduced 16.38%
8,170 $773,000
Q2 2018

Jul 09, 2018
BUY
$89.78 - $106.23 $26,934 - $31,869
300 Added 3.17%
9,770 $905,000
Q1 2018

Apr 27, 2018
BUY
$92.01 - $123.21 $230,025 - $308,025
2,500 Added 35.87%
9,470 $896,000
Q4 2017

Jan 17, 2018
SELL
$89.56 - $98.21 $1.32 Million - $1.44 Million
-14,700 Reduced 67.84%
6,970 $674,000
Q3 2017

Oct 16, 2017
BUY
$69.85 - $89.22 $1.51 Million - $1.93 Million
21,670
21,670 $1.93 Million

Others Institutions Holding ABBV

# of Institutions
4,263
Shares Held
1.27B
Call Options Held
18.2M
Put Options Held
15.5M
View Full List

About AbbVie Inc.

ABBV Quotes by TradingView
  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $324B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Cullinan Associates Inc Portfolio

Follow Cullinan Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullinan Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cullinan Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email